Allarity Therapeutics, Inc. ALLR
Allarity Therapeutics, Inc. (Nasdaq: ALLR) is an oncology drug developer. Its lead program, stenoparib, is in Phase 2 for platinum-resistant/ineligible ovarian cancer (DRP-guided); also relapsed SCLC with temozolomide.
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| stenoparib | platinum-resistant ovarian cancer (Phase 2, 40 pts, 2 dose levels) | small molecule | Phase 2 |
| stenoparib + temozolomide | relapsed small cell lung cancer (VA-funded randomized biomarker-driven trial) | small molecule | Phase 2 |
Recent results and decisions
- May 8, 2026positive Company presentation re-states Phase 2 stenoparib monotherapy median OS of 22 months (K-M) in 3rd-line+ DRP-selected ovarian cancer; median OS 24 vs 3 months above/below DRP 80 (HR 0.13, P=0.04).
Shows extended median Overall Survival - 22 months by K - M analysis
Filing - Mar 31, 2026started VA-funded Phase 2 trial of stenoparib plus temozolomide in recurrent SCLC opened at 11 VA centers, first patients dosed in early 2026.
the trial subsequently opened for enrollment across 11 VA medical centers in the United States, with the first patients dosed in early 2026.
Filing - Feb 18, 2026started First patients dosed with stenoparib plus temozolomide in the fully VA-funded Phase 2 trial in relapsed SCLC, open at 11 VA sites.
today announced that the first patients have been dosed with stenoparib and temozolomide in the VA-funded investigator-initiated Phase 2 trial for the treatment of relapsed small cell lung cancer (SCLC).
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 oncology companies
- Tango Therapeutics, Inc. TNGX
- Tyra Biosciences, Inc. TYRA
- Verastem, Inc. VSTM
- Obsidian Therapeutics, Inc. OBX
- Puma Biotechnology, Inc. PBYI
- Fulgent Genetics, Inc. FLGT
- Delcath Systems, Inc. DCTH
- Unknown Unknown
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.